Darunavir/ritonavir is recommended as a preferred third agent for use in
combination with tenofovir and emtricitabine in first-line treatment in British
HIV Association and US treatment guidelines.
Darunavir was initially licensed for treatment-experienced people on the
basis of the POWER 1 and 2, phase IIb study results. In these studies, two
different doses of boosted darunavir were compared with the effects of other
protease inhibitors in treatment-experienced people. After a 24-week analysis,
600mg darunavir and 100mg ritonavir was selected as the optimal dose and all
participants in the darunavir/ritonavir arm used that dosage.
Use of darunavir was approved at a dose of darunavir 600mg/ritonavir 100mg.1 2 Originally,
darunavir's use in the EU was limited to highly-treated adults who
had failed more than one regimen containing a protease inhibitor. In 2008, its
licensing was expanded to include any antiretroviral (ARV)-experienced
person.
In 2008, the US Food and Drug Administration expanded the indication for darunavir to
include its use as first-line therapy, dosed once daily. The protease inhibitor
was also given full approval for twice-daily use in all people with previous
ARV experience. This approval was based on data from the ARTEMIS
study.
In that study, results showed that people randomised to receive darunavir/ritonavir
had a non-inferior virological response after 48 weeks as compared to those
randomised to receive lopinavir/ritonavir (Kaletra).
However, those who started treatment with a viral load over 100,000 copies/ml
were significantly more likely to achieve a sustained undetectable viral load
if they received darunavir/ritonavir.3
Darunavir was licensed in the US for use in treatment-naive people dosed as
two 400mg tablets once daily with a 100mg boosting dose of ritonavir. In late
2008, once-daily dosing of boosted darunavir was approved in the US, dosed at darunavir
800mg/ritonavir 100mg, for a first-line regimen.
Darunavir/ritonavir has been compared with atazanavir/ritonavir, raltegravir
and dolutegravir in two clinical trials in previously untreated people.
In the ACTG 5257 study people treated with raltegravir were significantly
more likely to have undetectable viral load after 96 weeks when compared to
atazanavir/ritonavir or darunavir/ritonavir, but also more likely to develop
resistance after virological failure.4
In the FLAMINGO
study a significantly higher proportion of people who received dolutegravir
plus two nucleoside reverse
transcriptase inhibitors (NRTIs) had an undetectable viral load after 96 weeks
compared to darunavir/ritonavir (80% vs 68%). The difference between arms was
most pronounced in participants with high baseline viral load (> 100,000
copies/ml) (82% vs 52% response through week 96) and in people taking the
tenofovir/emtricitabine backbone (79% vs 64%). Virologic non-response to
treatment (dolutegravir 8%; darunavir/ritonavir 12%) and non-response due to
other reasons (dolutegravir 12%; darunavir/ritonavir 21%) occurred less frequently
with dolutegravir.5
For ARV-experienced people, the TITAN study compared twice daily
darunavir/ritonavir (600mg/100mg) with twice daily lopinavir/ritonavir capsules
(at the previous 400mg/100mg formulation), plus an optimised background regimen
selected by resistance testing.
After 48 weeks of treatment, intent-to-treat analysis showed that 77% of
those randomised to receive darunavir had viral load below 400 copies/ml,
compared with 68% of those randomised to receive lopinavir/ritonavir. This was
statistically significant and darunavir/ritonavir was seen as having
superiority over lopinavir/ritonavir in virologic suppression. A similar
difference emerged when the proportion of people with viral load below 50
copies/ml at week 48 was compared.6 On
the basis of this study, the drug was licensed for use in the EU for all
ARV-experienced people.
Once-daily 800mg/100mg darunavir/ritonavir dosing is also suitable for some
treatment-experienced people. The randomised, open-label ODIN trial found this
once-daily dose to be as effective at suppressing viral load after 48 weeks as
a 600mg twice-daily dose in treatment-experienced people who did not have
resistance mutations to darunavir at the start of the trial. The once-daily
dose was also less likely to cause lipid disturbances.7
The open-label GRACE study found that 600/100mg darunavir/ritonavir twice
daily, plus optimised background therapy, was equally effective in women and in
men after 48 weeks. There was little difference in side-effects, except that
women were somewhat more likely to report nausea.8
A caution has been issued that 0.5% of people taking darunavir/ritonavir
during its clinical development were diagnosed with drug-induced hepatitis. See the Side-effects
section for more information on this topic.